Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies

Ali Keshavarz1†, Ali Salehi2†, Setareh Khosravi3, Yasaman Shariati4, Navid Nasrabadi5, Mohammad Saeed Kahrizi6, Sairan Maghsoudi7, Amirhossein Mardi8, Ramyar Azizi9, Samira Jamali10* and Farnoush Fotovat11*

Abstract
Advancements in adoptive cell therapy over the last four decades have revealed various new therapeutic strategies, such as chimeric antigen receptors (CARs), which are dedicated immune cells that are engineered and administered to eliminate cancer cells. In this context, CAR T-cells have shown significant promise in the treatment of hematological malignancies. However, many obstacles limit the efficacy of CAR T-cell therapy in both solid tumors and hematological malignancies. Consequently, CAR-NK and CAR-M cell therapies have recently emerged as novel therapeutic options for addressing the challenges associated with CART-cell therapies. Currently, many CAR immune cell trials are underway in various human malignancies around the world to improve antitumor activity and reduce the toxicity of CAR immune cell therapy. This review will describe the comprehensive literature of recent findings on CAR immune cell therapy in a wide range of human malignancies, as well as the challenges that have emerged in recent years.

Keywords: Immunotherapy, Chimeric antigen receptors, CART-cell, CAR-NK cell, CAR-M solid tumors, Hematological malignancies

Introduction
Malignant tumors are a primary global health concern, with increasing annual incidence and a high mortality rate. Surgery, chemotherapy, and radiation were the sole options for treating malignant tumors for decades [1]. In recent years, immune-based therapies such as chimeric antigen receptor (CAR)-modified immune cells have emerged as promising alternative treatments. Typically, the immune system eliminates potentially malignant cells, but cancer cells can acquire specific mutations that allow them to evade these mechanisms. Cancer immunotherapies aim to support or boost the patient’s immune system so that cancer cells can be effectively eradicated [2]. One approach is to genetically modify immune cells, mainly T-cells and, more recently, natural killer (NK) cells and macrophages to express CARs. CAR expression on immune cells enables them to specifically target cancer cells by recognizing tumor-associated antigens (TAAs) [3]. Classical CARs are made up of an antigen recognition extracellular domain mainly derived from a monoclonal antibody fragment linked to intracellular T-cell receptor (TCR) complex binding domains [4] (Fig. 1). CAR binding to cell surface antigens is independent of the major histocompatibility complex (MHC) receptor, resulting in robust T-cell activation and potent antitumor responses [5]. CAR T-cells have demonstrated remarkable results in the treatment of relapsed or refractory hematological malignancies, culminating in the...
approval of six drugs by the Food and Drug Administration (FDA) between 2017 and the beginning of 2021 [6]. However, there are significant limitations to CAR immune cell therapy that must be addressed, such as life-threatening toxicities, diminished efficacy against solid tumors, limited durability, antigen escape, poor infiltration into the tumor, and the immunosuppressive features of the microenvironment [7]. On the other hand, many approaches, such as combining CAR immune cell therapy with other anticancer therapies or employing novel CAR engineering strategies, have been proposed to expand clinical efficacy, improve antitumor potency, and limit toxicities [4, 7]. In this review, we discuss ongoing innovations in CAR immune cell engineering to enhance clinical efficacy in solid tumors and hematological malignancies, as well as limitations of CAR immune cell therapy.

**Immune cells dysfunctions in the tumor microenvironment**

The immune system has a crucial role in cancer growth control. Cancers, on the other hand, evolve to avoid detection by the immune system. Cancer growth and progression are a result of immune tolerance and active immune cell suppression [8]. The physiologic tumor microenvironment (TME) is a significant contributor to immune tolerance. Hypoxia, hypoglucosis, lactosis, acidity, and nutrient deprivation are the aspects of the complicated TME that can sustain tumor growth, promote immune escape, and enhance immunosuppressive features. Moreover, changes in the signal transduction molecules, loss of tumor-specific antigens (TSAs), stimulation of the inhibiting receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) on T-cells as well as some soluble molecules (interleukin (IL)-10, type I interferons (IFNs), Indoleamine 2,3-Dioxygenase (IDO), adenosine, vascular endothelial growth factor A (VEGF-A), transforming growth factor-beta (TGF-β), and IL-35) secreted by tumor cells or non-tumor cells in the TME mediate immune cell dysfunction [9]. In addition, the TME contains several immunosuppressive cells that contribute to immune cell dysfunction. Regulatory T-cells (Tregs), myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), and cancer-associated fibroblasts are examples of inhibitory cells [10, 11, 12] (Fig. 2). Immune-related therapies have been established to reverse dysfunctional immune cells and restore antitumor immunity. As a result, cancer patients gained many hopes for this approach. Currently, immunotherapy focuses on CAR-expressing immune cells in patients with various solid tumors and hematological malignancies [10].

**CAR structure and CAR-modified immune cells generation process**

CAR-based genetically modified immune cells express synthetic receptors that efficiently redirect immune cells to the surface antigens on the tumors for tumor eradication via immune cell cytotoxicity. The typical structure of a CAR molecule consists of an extracellular antigen recognition domain (ectodomain), an extracellular hinge domain, a transmembrane domain, and one or more intracellular signaling endodomains [13, 14] (Fig. 1). The ectodomain is known as the antigen recognition region and comprises a single-chain variable fragment (scFv) that targets a specific TAA. CAR T-cells’ ectodomain (scFv) can recognize TAA on tumor cells without the need for classical antigen processing and presentation by the MHC, which is one of the main features of CAR T-cells. The hinge component (spacer) is responsible for connecting the ectodomain to the transmembrane domain. The transmembrane domain, hydrophobic alpha-helix, extends across the membrane between the spacer and the signaling end domains. [15, 16, 17]. The endodomain (signaling domain) is the functional component of CAR immune cells that controls their activation, proliferation, and survival. The CAR endodomain delivers costimulatory signals to immune cells in response to antigen recognition by the ectodomain, allowing them to initiate their cytotoxic function [17] (Fig. 1).

Four generations of CAR T-cells were constructed based on the endodomain structure [18]. The first generation of CARs had scFv attached to a single intracellular signaling domain, CD3. For efficient T-cell activation, two distinct signals are required. The interaction of the foreign peptide presented by the MHC complex with the TCR expressed on T-cells provides signal 1, and the interaction of costimulatory B7 molecules [B7.1 (CD80) or B7.2 (CD86)] expressed on the antigen-presenting cells with the co-receptor protein CD28 expressed on the T-cells provides signal 2 [19]. However, the first generation of CARs structure could only provide signal 1. Hence, T-cells are unable to carry out their efficient cytotoxic activity if costimulatory signal 2 is missing. As a result, the first CAR T-cell generations were ineffective, with low proliferation and high apoptotic potential [20]. To improve the limitations of the first CAR generation, in the second generation of CARs, two intracellular signaling domains (such as CD28 or 4–1BB) were introduced to the cytoplasmic tail of CARs [21]. In the third generation of CARs, Three costimulatory domains were introduced to improve T-cell activation signals and modify T-cell survival, produce more cytokines, and have a better antitumor cytotoxic effect [22, 23]. Finally, by adding a cytokine inducer to the base of a second-generation or the third-generation construct, the fourth generation of
2. CAR structure and generations

A. CAR structure and mechanism of action

![Diagram of CAR structure and mechanism of action]

B. CAR T-cell generations

![Diagram of CAR T-cell generations]

C. CAR NK-cell generations

![Diagram of CAR NK-cell generations]

Fig. 1 Chimeric antigen receptors' structure and generations. A CAR structure and mechanism of action. B CAR T-cell generations. C CAR NK-cell generations. Abbreviations: CAR (Chimeric antigen receptor), TAAs (tumor-associated antigens), NFAT (Nuclear factor of activated T-cells)
CAR T-cells, also known as T-cells redirected for universal cytokine killing (TRUCKs), was established [24, 25]. Likewise, next-generation CAR T-cells are currently underway. The new generation, already named the fifth generation, is based on the second-generation CARs with the addition of an IL-2 receptor β (IL-2R β) fragment. By mRNA transcription, the IL-2R β fragment can induce the production of Janus kinases (JAKs) and signal transducer and activator of transcription (STAT)-3/5 [18].

Additionally, other immune cells with antitumor function, like NK cells, demonstrate a promising potential to replace T-cells and for utilized in universal immune cell therapy, so researchers have focused on developing CAR-NK cells [26]. Although CAR constructs optimized for T-cell signaling were employed in early preclinical investigations of CAR-NK cells and some key costimulatory domains used in CAR design, such as 4–1BB, are shared by tumor cells or non-tumor cells in the TME all contribute to immune cell dysfunction. Moreover, the TME contains immunosuppressive cells (Tregs, MDSCs, TAMs, and CAFs) which contribute to immune cell dysfunction. Abbreviations: TME (tumor microenvironment), TSAs (tumor-specific antigens), CTLA-4 (cytotoxic T-lymphocyte-associated antigen 4), IFNs (interferons), IDO (Indoleamine 2,3-Dioxygenase), VEGF-A (vascular endothelial growth factor A), TGF-β, transforming growth factor-beta, Tregs (Regulatory T-cells), MDSCs (myeloid-derived suppressor cells), TAMs (tumor-associated macrophages), CAFs (cancer-associated fibroblasts)

**Immune cells sources**
The majority of current CAR T-cells are made of harvested T-cells from patients. However, a high burden of tumors and a lack of T-cell population, particularly in patients with T-cell malignancies or those who have
received chemotherapies, have made it challenging to obtain a sufficient quantity of competent T-cells by apheresis. In addition, allogeneic CAR T-cell therapy has been demonstrated to be effective in patients with suitable donors, and speculation that allo-hematopoietic stem-cell transplantation (HSCT) causes severe graft-versus-host disease (GVHD). Nevertheless, allo-CAR T-cell treatment is costly and time-consuming even for patients who meet the donor-matching requirements (Table 1) [28, 29].

Unlike T-cells, NK cells have a lower risk of GVHD, opening the path to producing “off-the-shelf” allogeneic cell therapy agents that can be prepared ahead of time and made available to a large number of patients on demand [38]. Clinical-grade NK cells can currently be produced in large quantities using a variety of sources (Table 1) [39].

### Similarities and differences between CAR T-cells and CAR-NK cells

With the dramatic success of CAR-engineered T-cells in the treatment of hematological cancers, there are flaws in CAR T-cell therapy’s broad therapeutic application. On the other hand, CD8+ cytotoxic T-cells and NK cells are two types of immune cells that use similar cytotoxic mechanisms to kill target cells [40]. As a result, there is a growing interest to develop CAR-engineered NK cells as a low-cost cancer therapy [41]. CAR-NK cells may have some significant advantages over CAR T-cells [27, 42]. Currently, CAR T-cells are made by collecting blood from the patients, creating the CAR T-cells, and then administering them to the patient. This takes two main items to consider. One is the cost, and second, some patients with particularly aggressive illnesses may not have the four or six weeks required for CAR engineering. Nonetheless,
with CAR-NK cells, we can have an off-the-shelf product so that the patient comes into your clinic and you have these cells frozen, sitting in a biobank, and you can thaw and infuse, making the strategy lot more appealing and also cheaper [7, 43]. In addition, CAR-NK cells are safer than CAR T-cells because the cytokines secreted by activated NK cells (e.g., IFN-γ and granulocyte–macrophage colony-stimulating factor (GM-CSF) are safer and typically eliminate the risk of cytokine storm and extreme neurotoxicity caused by pro-inflammatory cytokines (tumor necrosis factor-alpha (TNF-α), IL-1, and IL-6) released by CAR T-cells [44], and also allogeneic CAR-NKs decrease the risk of GVHD because they are not restricted to MHC [45]. Moreover, CAR-NK cells may have multiple mechanisms for cytotoxic activity because they can recognize and kill targets via engineered killing capacity as well as their intrinsic killing capacity via natural cytotoxicity receptors [46, 47]. Furthermore, CAR-expressing NK cells enable the eradication of heterogeneous malignancies in which some malignant cells lack CAR targeted specific antigens [48]. Indeed, mature NK cells have a shorter lifespan in the bloodstream, which reduces the risk of long-term cell deficiency caused by cellular memory responses and on-target/off-tumor effects [43]. Furthermore, because of the low risk of allo-reactivity and GVHD, allogenic CAR-NK cells could potentially be obtained from various sources, including PB, UCB, iPSCs, hESC, and NK-92 cell lines [49, 50]. Despite many advantages of NK cells, the utilization of CAR-NK cells in clinical trials faces some challenges. The current CARs used in NK cells have a structure that causes the first reluctance. The epitopes binding to the current CAR’s position, as well as their space from the CAR-NK cell’s surface, reduce the ability of these cells to bind antigens and stimulate CAR-NK cells [51]. NK cells are also more susceptible to freezing and thawing, which reduces their antitumor capacity and survival rate [52]. Indeed, because infused CAR cells do not persist in the absence of cytokine assistance, exogenous cytokines must be given in a certain order for infused NK cells to survive and proliferate in vivo. Exogenous cytokines, on the other hand, might have adverse consequences such as systemic toxicity [53, 54]. The final issue stems from the lack of an effective gene transfer strategy in NK cells [55] retro- and lentiviral vectors were used in most studies on viral transduction of NK cells, but their use has been limited. This could be due to innate NK cell properties like pattern recognition receptors that identify foreign genomic material, which is probably associated with triggering NK cell apoptosis after viral transduction. In addition, electroporation or lipofection can be used to transfer genes via transfection. Transfection of NK cells is found to be correlated with lower levels of apoptosis and transgene transport efficacy that is fully independent of cellular division as compared to viral transduction [56] (Table 2). Finally, it is essential to note that unlike CAR T-cells, CAR-NK cell studies are still mostly preclinical, but there is a lot of promise from CAR-NK cell-based studies. Therefore, we need to wait and see how well they act in the clinic.

**CAR-modified immune cells in hematological malignancies**

**Lymphoma**

For lymphoma, the most common therapies were chemotherapy regimens and monoclonal antibodies. Although these agents were successful to some extent, some patients’ diseases deteriorated even after primary and secondary therapies [57]. However, there is a novel and effective alternative treatment for patients who have

| Table 2 | Comparison between CAR T-cells and CAR-NK cells |
|---------|-----------------------------------------------|
| **Parameter** | **CAR T-cells** | **CAR-NK cells** |
| Sources | Mainly autologous T-cells | Variety of sources, including PB, UCB, HPCs, hESC, iPSCs, and cell lines |
| Safety | May causes GVHD and cytokine storm | Safer, reduce the risk of cytokine storm and GVHD |
| Cytotoxic mechanism | CAR-restricted cytotoxicity | Multiple mechanisms for cytotoxic activity, CAR killing capacity as well intrinsic killing capacity via natural cytotoxicity receptors |
| HLA restriction | No HLA restriction | No HLA restriction |
| Transduction | Higher transduction efficacy | Low transduction efficacy |
| Persistence | Better persistence | Low persistence, need to exogenous cytokines |
| Stability | Less susceptible to freezing and thawing | More susceptible to freezing and thawing |
| Life span | Longer | Shorter |
| Cost of production | Expensive | Cheaper |
| Construction to injection period | Longer period of time (4–6 weeks) | Short period time, off-the-shelf |

PB, peripheral blood; UCB, umbilical Cord blood; HPCs, hematopoietic progenitor cells; hESC, human embryonic stem cell; iPSCs, induced pluripotent stem cells; GVHD, Graft-versus-host disease; HLA, human leukocyte antigen
failed multiple lines of therapy [58]. Therefore, immune cell therapy with CAR T-cell has transformed the treatment of lymphomas, particularly for aggressive B-cell lymphomas. As a result, the FDA has licensed four anti-CD19 CAR T-cells for aggressive B-cell lymphoma (axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel and lisocabtagene ciloleucel). Although these products have different CAR designs, costimulatory domains, manufacturing processes, doses, and pivotal trial eligibility criteria, all four CAR T-cells generate long-term remissions in 33–40% of treated patients [59].

Axicabtagene ciloleucel (axi-cel) is an anti-CD19 CAR T agent delivered via retrovirus using a CD28 costimulatory signal. The ZUMA-1 trial was a landmark study that examined axi-cel and resulted in the first FDA approval of CAR T-cell therapy to treat large B-cell lymphomas in 2017 [60, 61]. Tisagenlecleucel (Kymriah) is another anti-CD19 CAR T agent that uses lentivirus-based vector delivery with a 4-1BB costimulatory signal. The JULIET trial (NCT02445248) was a global phase II trial that demonstrated tisagenlecleucel to have high response rates and a long duration of action in adults with refractory or relapsed diffuse large B-cell lymphoma (DLBCL) [62]. Brexucabtagene autoleucel (Tecartus) is another anti-CD19 CAR T that was approved in 2020 for the mantle cell lymphoma (MCL) treatment and recently for ALL based on ZUMA-2 (NCT02601313) and ZUNA-3 (NCT02614066) trials [63, 64]. The last FDA-approved agent is Lisocabtagene maraleucel (liso-cel; JCAR017), a CD19-directed 4-1BB CAR T product for the treatment of adult patients with refractory or relapsed large B-cell lymphoma [65]. Besides CD19, some other surface biomarkers are essential. CD20, a transmembrane protein found in more than 90% of B-cell lymphomas, is a well-known target for non-Hodgkin lymphoma (NHL) treatment [66]. Several studies are currently using first-generation anti-CD20 CAR T-cell therapy (NCT04160195, NCT03576807, NCT03019055). Another possible target is CD30. Classical Hodgkin lymphoma (HL), anaplastic large cell lymphoma, DLBCL, primary mediastinal B-cell lymphoma, and peripheral T-cell lymphoma all express CD30 [67, 68]. Furthermore, the use of Epstein-Barr virus (EBV)-specific CAR T-cells that recognize and kill EBV-infected cells may protect

### Table 3

| Type of malignancy             | CAR-NK Cell product                      | Phase stage | Status         | Last update posted | Identifier       |
|--------------------------------|------------------------------------------|-------------|----------------|-------------------|-----------------|
| B-cell NHL, ALL, CLL, WM       | Allogeneic CAR-NK cells targeting CD19   | Phase 1     | Recruiting     | November 17, 2021 | NCT05020678     |
| Multiple myeloma               | Anti-BCMA CAR-NK Cells                   | Early Phase 1| Recruiting     | November 23, 2021 | NCT05008536     |
| AML/MDS                        | Allogeneic CAR-NK targeting NKG2D        | Phase 1     | Recruiting     | May 17, 2021      | NCT04623944     |
| AML                            | anti-CD33 CAR-NK cells                   | Phase 1     | Recruiting     | August 17, 2021   | NCT05008575     |
| B-cell NHL, ALL, CLL           | CAR-NK-CD19 Cells                        | Phase 1     | Recruiting     | April 8, 2021     | NCT04796675     |
| Hematological malignancy       | CD5 CAR-engineered IL15-transduced cord blood-derived NK cells | Phase 1 | Recruiting | November 8, 2021 | NCT05110742     |
| B-cell Lymphoma, ALL, CLL      | CAR-NK-CD19 Cells                        | Phase 1     | Recruiting     | March 15, 2021    | NCT04796688     |
| Multiple Myeloma               | BCMA CAR-NK 92 cells                     | Phase 1     | Recruiting     | May 7, 2019       | NCT03940833     |
| NHL                            | Anti-CD19 CAR-NK                         | Early Phase 1| Not yet recruiting | November 20, 2020 | NCT04639739     |
| B-cell NHL                     | Anti-CD19 CAR-NK                         | Phase 1     | Recruiting     | May 14, 2021      | NCT04887012     |
| B-Cell lymphoma, MDS, AML      | CAR-70- Engineered IL15-transduced Cord Blood-derived NK Cells | Phase 1 | Not yet recruiting | November 2, 2021 | NCT05092451     |
| B-cell NHL                     | CD19 CAR-NK cell therapy (TAK-007)       | Phase 2     | Not yet recruiting | November 11, 2021 | NCT05020015     |
| Malignant tumor                | ROBO1 BiCAR-NK/T-cells                   | Phase 1     | Recruiting     | April 30, 2019    | NCT03931720     |
| Glioblastoma                   | HER2-specific, CAR-expressing NK-92 cells (NK-92/5.28. z) | Phase 1 | Recruiting | September 25, 2020 | NCT03383978     |
| Prostate cancer                | Anti-PSMA CAR-NK cells                   | Phase 1     | Not yet recruiting | October 2, 2018   | NCT03692663     |
| Gastroesophageal junction cancers, Advanced HNSCC | PD-L1 CAR-NK Cells | Phase 2 | Recruiting | November 23, 2021 | NCT04847466     |
| Pancreatic cancer              | ROBO1 CAR-NK cells                       | Phase 1     | Recruiting     | May 8, 2019       | NCT03941457     |
| Solid tumors                   | ROBO1 CAR-NK cells                       | Phase 1     | Recruiting     | May 7, 2019       | NCT03940820     |

HNSCC, Head and neck squamous cell carcinomas; NHL, Non-Hodgkin lymphoma; ALL, Acute lymphoblastic leukemia; CLL, Chronic lymphocytic leukemia; MW, Waldenstrom macroglobulinemia; AML, Acute myeloid leukemia; MDS, Myelodysplastic syndrome
against the recurrence of EBV-related B-cell NHLs such as BL and DLBCL. The κ or λ light immunoglobulin chain expressed in some mature malignant B-cells and anti-κ/λ CAR T-cells are also potential strategies for the treatment of B-cell lymphoma [67].

CAR-NK cells have also been investigated in the treatment of lymphoma (Table 3). The safety and efficacy of anti-CD19 and anti-CD20 CAR-NK cells against B-cell malignancies were primarily investigated in preclinical studies with CAR-NK cells, but outcomes with first-generation CARs were modest [69]. Liu et al. revealed that genetically modified NK cells from cord blood using a retroviral vector expressing a fourth-generation CAR vector (iC9.CAR19.CD28.CD28ζ-IL-15) exhibited remarkable antitumor activity in xenograft mouse models of Raji tumor activity [70]. Chu et al. also used mRNA nucleofection to genetically modify peripheral blood NK cells from healthy donors to express anti-CD20 CAR. In preclinical models, this approach resulted in 67% CAR expression and significant in vitro and in vivo efficacy against Burkitt lymphoma [71]. Chen et al. found that third-generation anti-CD5 CAR Transduced NK-92 cells with CD28 and 4-1BB costimulatory domains have potent in vitro cytotoxicity against primary patient-derived -cell acute lymphoblastic leukemia (T-ALL), T-cell lymphoma, and Sezary cells, as well as enhanced survival in a Jurkat lymphoma xenograft mouse model [72].

Leukemia

Although CAR T-cell therapy has been shown to be highly effective in treating ALL and that two CD19-CAR T-cell therapies (tisagenlecleucel and Brexucabtagene autoleucel) have been approved by the FDA for the treatment of refractory or relapsed ALL, relapsing ALL blasts with down-regulated or abrogated CD19 expression remain a critical barrier to maintaining permanent remissions [73, 74]. As a result, backup antigens such as CD22 have received increased attention. In a recent clinical trial, CD22-CAR T-cells were shown to have the potential to mediate complete remissions in patients with relapsing CD19-negative blasts [75, 76]. Although evidence with CAR T-cells in chronic lymphocytic leukemia (CLL) therapy is limited, safety and efficacy outcomes are promising, implying that CAR T-cells might be employed in CLL patients with a dismal prognosis [77]. Although several target antigens, including CD20 [78], ROR1 [79], CD23 [80], and κ-light chain [81], were studied in CLL, the most promising clinical data, similar to ALL, was obtained using CD19-CAR T-cells [82]. Despite this, the overall complete remission rate for CD19-CAR T-cells in CLL was only 29% [82]. CLL patients’ T-cells have been shown to acquire proliferative and metabolic dysfunctions, which may contribute to the lower efficacy of CAR T-cell therapy in CLL [83]. Unlike ALL and CLL, clinical knowledge on CAR T-cells in acute myeloid leukemia (AML) is still being developed. The main barrier to applying CAR T-cell therapy to myeloid malignancies is the lack of distinct target antigens that distinguish malignant cells from healthy progenitor cells [84]. A number of target antigens have been proposed for a long time, including CD123 [85], LeY antigen [86], folate receptor-β [87], and CD33 [88]. CAR T-cells targeting Lewis-Y on myeloid blasts provided proof-of-principle results for CAR T-cell efficacy in AML, but there was no report of long-term remission [89]. CD123 and CD33 have appeared as the premier target antigens getting the most attention in current clinical trials due to their universal presence in primary diagnosis and relapsed myeloid blasts [90, 91]. In a current trial, CAR T-cells targeting CD123, which is expressed on leukemia-initiating cells, were found to elicit full remissions (NCT02159495) [89]. FMS-like tyrosine kinase 3 (FLT3) is another promising target antigen that could be successfully exploited using FLT3-targeting CAR T-cells demonstrating potent reactivity against AML blasts expressing wild-type or FLT3 with internal tandem duplication (FLT3-ITD) [92].

A phase I clinical trial of CD33-CAR-NK cells reported the safety of CAR-NK cell therapy for relapsed and refractory AML patients [93]. Another study indicated that FLT3-CAR-NK cells might successfully target B-ALL [94]. Furthermore, CD19-CAR-NK-92 cells inhibited leukemia growth in a B-cell lymphoma mouse model [95]. On the other hand, AML blasts are extremely sensitive to NK cell-mediated toxicity as they express several of the ligands identified by NK cell activation receptors. As a result, CAR-NK cells may be able to overcome some of the hurdles associated with antigen evasion and tumor heterogeneity in AML through their innate ability to detect and target AML cells [27, 96]. Thus, attempts to develop CAR-NK cells against AML are now underway. A recent study showed that primary human NK cells with anti-CD123 and dual co-stimulation with CD28 and 4-1BB successfully destroyed AML cell lines and primary AML blasts in vitro [96]. In another investigation, Salman et al. demonstrated that injecting CD4-CAR-NK cells into a systemic AML implanted murine model may enormously boost anti-leukemic effects [97]. In addition, CAR-NK cell therapy may be effective in the treatment of T-cell-related leukemia. CD7-CAR-NK-92 demonstrated selective and potent antitumor activity against T-ALL cell lines and T-ALL xenograft mouse models, which could be mediated by increased granzyme B and IFN-γ secretion [98, 99].
Myeloma

Even though CD19 CAR T-cells demonstrated remarkable results in treating certain B-cell malignancies, it was unable to effectively eliminate myeloma cells due to the lower expression of CD19 on the surface of myeloma cells [100, 101]. Therefore, alternative markers were considered, and B-cell maturation antigen (BCMA) received the most remarkable attention [102, 103]. BCMA, a tumor necrosis factor (TNF) receptor superfamily member that binds both B-cell activating factor and a proliferation-inducing ligand (APRIL), is widely and almost exclusively expressed on plasma cells and B-cells [104]. Early clinical trials with BCMA CAR T-cells in strongly pretreated individuals demonstrated a high response rate; however, relapses did occur [105]. As anti-BCMA trials were done and relapses were identified, a variety of markers were investigated as prospective targets, including APRIL [106], CD138 [107], kappa light chain [81], CS1 glycoprotein antigen (SLAMF7) [108], GPRC5D [109], CD38 [110], CD229 [111], Lewis-Y (NCT01716364), and NKG2D ligands [112]. Although the cohorts were small, treatment efficacy ranged from no response to 80%, with many complete remissions recorded [113]. In addition, CD19-targeted CAR T-cells used in combination with autologous stem-cell transplantation have shown efficacy in relapsed/refractory multiple myeloma [114].

Myeloma cells are also susceptible to NK cell-mediated death as they express various ligands for NK receptors [115]. Hence, there is much interest in creating CAR-NK cells that target myeloma antigens such as CS1 (CD319), CD138, and BCMA [69]. Therefore, we transduced NK-92 cells with a lentiviral vector expressing a first-generation anti-CD138 CAR or a second-generation anti-CS1 CAR.CD28. It demonstrated in vitro and in vivo activity against myeloma [116]. Similarly, an investigation into the potential therapeutic effects of CD38-specific nanobody-based CAR (Nb-CARS) revealed that Nb-CAR-NK-92 cells might induce cytotoxicity against primary patient-derived CD38-expressing myeloma cells [117].

CAR-modified immune cells in solid tumors

CAR immune cell therapy has developed as an immuno-therapy modality, and after achieving remarkable success in hematological malignancies, it is now being extensively studied in advanced solid tumors. However, unlike in hematological malignancies, CAR immune cell application in solid cancers has been limited by a number of challenges. Several methods have been developed to overcome these limitations, including localized delivery of CARs, genetic alterations, and combination therapy [118]. Overall, 22 targets are being studied in patients with solid tumors in ongoing or published clinical trials around the world (FR-α, MSLN, human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), carcinoembryonic antigen (CEA), MUC1, GD2, epithelial cell adhesion molecule (EpCAM), carbonic anhydrase IX (CAIX), L1-CAM, EGFRvIII, IL13Rα2, prostate-specific membrane antigen (PSMA), PSCA, fibroblast activation protein (FAP), CD133, c-MET, ephrin type-A receptor 2 (EphA2), Glypican-3 (GPC3), VEGFR-2, ROR1, MUC16) [119].

Breast cancer

Triple-negative breast cancer (TNBC) is the complex and the most challenging subtype of breast cancer, with a very high recurrence rate and a poor prognosis, necessitating a substantial effort to identify novel treatment options [120]. The initial step to creating successful CAR therapies for TNBCs is the selection of relevant cell surface antigens. TSAs are ideal CAR targets since they contribute to cancer pathobiology and are shared by cancer patients. However, TSAs expressed in a high ratio of patients with cancer are limited [121]. Antigens that are now being targeted in breast cancer clinical research include HER2, mesothelin, CEA, CAIX, FR-α, CD171, GD2, EGFRvIII, FAP, and vascular endothelial growth factor receptor 2 (VEGF-R2) [122, 123, 124]. Mucin 1 (MUC1) is expressed in more than 90% of breast cancers, making it the most relevant and significant antigen for breast cancer targeting. Furthermore, MUC1 is expressed on 95% of TNBC. Zhou et al. demonstrated that the destruction of TNBC tumors by TAB004-derived MUC28z CAR T-cells is effective in vitro and in vivo [125]. Because MUC1 is expressed in the majority of epithelial-derived solid tumors, such as breast cancer subtypes, MUC28z CAR T-cells will most likely have extensive applicability for solid tumor targeting [125]. Breast cancer recurrence and, ultimately, survival are known to be influenced by HER-2 expression. HER-2-targeted therapies are now an essential part of the therapy of HER-2 overexpressing breast cancer [126]. Several HER-2-targeted CAR T-cell clinical trials are currently underway, including a phase I HER2-targeted dual switch CAR T-cell (BPX-603) in subjects with HER2-positive solid tumors (NCT04650451) and a phase 1 combination of binary oncolytic adenovirus in advanced HER2-positive solid cancers with HER2-specific autologous CAR VST (NCT03740256). Tchou et al. showed overexpression of mesothelin in 67% of TNBC samples, with minimal expression in other breast cancer subtypes and no expression in normal breast epithelial cells. Moreover, CAR T-cells specific for mesothelin showed cytotoxicity against TNBC cells [127]. TNBC immunotherapy using CAR T-cells is still in its early stages, but it has much promise. Target selection, CAR creation, preclinical
and clinical testing, and techniques to improve safety and boost the CAR T-cell immunotherapy response are all part of the current work, which is critical to the success of immunotherapy in TNBC and other solid cancers [128].

On the other hand, breast cancer is a potent target for CAR-NK therapy [129]. An in vitro analysis revealed that ErbB2-CAR-NK-92 cells successfully eradicated ErbB2+ breast cancer cells [31]. Hu et al. showed that tissue factor (TF) targeted NK cells efficiently destroyed TNBC cells in vitro and a TNBC xenograft model [130]. Indeed, Liu et al. found that employing EGFR-CAR-NK cells accurately triggered in vitro lysis of TNBC cells and suppressed tumor development in a mouse model [131].

**Ovarian cancer**

There are two main advantages of studying CAR T-cells for ovarian cancer (OC) treatment. First, OC cells express a wide range of TAAs [132]. Aside from CA125, the cancer cell expresses more than 60 TAAs. This increases the number of targets available for CAR T-cell design [133]. To date, TAAs found in OC include MUC16, HER2, hepatocyte growth factor receptor (c-Met), mesothelin, folate receptor alpha (FRα), cancer/testis antigen 1B, and cancer antigen 125 [134, 135]. MUC16, highly glycosylated mucin that is overexpressed in the majority of OCs, has been identified as a surrogate blood biomarker (CA-125) for the diagnosis and prognosis of OCs [136]. CAR-modified MUC16-targeted T lymphocytes exhibit intense specific cytotoxic activity against MUC16+ OC cells in vitro [137]. Moreover, in a humanized murine model of OC designed to express human mesothelin, mesothelin-targeted IVT CAR T-cells effectively reduced tumor growth [138]. Human FRα-directed IVT mRNA CAR T-cells destroyed human OC cell lines OVCAR3, A187, and SKOV3 in vitro conditions. Furthermore, FRα-targeted mRNA reduced cancer cell proliferation in both localized and diffused mouse models of OC [139]. Finally, the second benefit is that CAR T-cell administration can be accomplished via intraperitoneal injection (IP) instead of intravenous injection (IV). This is attributable to the fact that the peritoneal cavity is the leading site of OC metastases [140].

In addition, explicitly utilizing FRα-specific CAR-NK-92 cells led to the selective lysis of FRα+ tumor cells in vitro and a mouse xenograft OC model [141]. Furthermore, in vitro, mesothelin-specific CAR-NK cells were able to eradicate mesothelin-positive OC cells selectively [142]. Other research has recently revealed that co-expression of the chemokine receptors CXCR1 and CAR may provide a unique strategy for improving the therapeutic effectiveness of NK cells in human OC by increasing tumor penetration of effector immune cells [143].

**Lung cancer**

Lung cancers are a leading cause of cancer-related mortality, with high resistance to chemotherapies [144], emphasizing the importance of CAR-based therapies for these tumors. A significant proportion of CAR T-cell research in solid tumors is focused on non-small cell lung cancer (NSCLC) [145]. Mesothelin (MSLN), EGFR, PSCA, MUC1, CEA, CD80/CD86, programmed death-ligand 1 (PD-L1), inactive tyrosine-protein kinase transmembrane receptor (ROR1), and HER2 are the most frequently targeted antigens in NSCLC [146]. Also, Kitakyushu lung Cancer Antigen-1 (KK-LC-1) is recognized as a potential immunotherapy antigen for lung cancer and some other solid tumor immunotherapy [147]. Other antigens targeted with lung cancer CAR T-cells in clinical trials include Lewis-Y antigen, ganglioside GD2, melanoma-associated antigen (MAGE)-A1, and MAGE-A4 (NCT03198052 and NCT03356808). Mesothelin is one such antigen found in high concentrations in most lung cancers. In patients with early-stage lung adenocarcinoma, mesothelin overexpression is significantly associated with tumor aggressiveness and a lower survival rate [148]. This has resulted in the development of multiple safety methods, which are currently being investigated in multiple clinical trials for mesothelin-targeted CAR T-cell immunotherapy, including NCT01583686. HER2 overexpression was also identified in NSCLC and is shown with a poor prognosis [149]. Currently, numerous clinical trials evaluate the efficacy of HER2-targeted CAR T-cells for HER2-positive solid tumors, including NSCLC (NCT02713984, NCT03740256). CAR T-cell against PD-L1 is also investigated in phase 1 trial of advanced PD-L1-positive NSCLC patients (NCT03330834) (NCT03330834). Wallstabe et al. recently demonstrated that anti-ROR1 CAR T-cells successfully eradicated NSCLC and TNBC cells in three-dimensional tumor models. As a result, anti-ROR1 CAR T-cell therapy provides a new approach to treating NSCLC [150]. Hu et al. developed a CAR T-cell-based method to target lung-specific X receptors (LunX). CARLunX-T-cells exhibited increased toxicity toward NSCLC in vitro and were extensively studied. They also developed a patient-derived xenograft model of lung cancer and demonstrated that survival was incredibly prolonged[151]. Overall, the therapeutic applicability of CAR T-cells in lung cancer treatment is still being researched extensively. However, the continuing progression of CAR T-cell therapy for lung cancer shows great promise.

On the other hand, in animal models of lung cancer, Wang et al. found that inhibiting CD73 increases homing of NKG2D-CAR-NK cells, which target tumor cells expressing NKG2D ligands, and improves antitumor responses [152].
Colorectal cancer

Colorectal cancer (CRC) refers to colon and rectal epithelial tissue cancers that primarily affect the elderly and have a poor prognosis [153]. Various promising CAR T-cell-based therapeutic targets have been proposed in preclinical models for CRC, including CEA, EGFR, MUC1, NKG2D, HER2, and CD133 with many therapeutic strategies [154, 155]. Hedge et al. published one of the first human studies utilizing first-generation retrovirus products to investigate their efficacy in CRC treatment [156]. As a result, CAR T-cell therapy could be a potential therapeutic option for CRC patients in the future.

As CAR T-cells in the treatment of CRC, but not all trials. According to the studies described, some clinical trials have shown the safety and efficacy of immunotherapy-based CAR T-cells in the treatment of CRC, but not all trials. As a result, CAR T-cell therapy could be a potential therapeutic option for CRC patients in the future.

Besides CAR T-cell, some studies also applied NK CAR products to investigate their efficacy in CRC treatment. Zhang et al. transduced the EpCAM-CAR by using a lentiviral vector on the NK-92 cell line. Anti-EpCAM-CAR-NK-92 cells demonstrated potent antitumor cytotoxicity and cytokine production in EpCAM + colorectal cancer cells. Injecting anti-EpCAM-CAR-NK-92 cells into a CRC xenograft model in conjunction with regorafenib, a protein kinase inhibitor, successfully inhibited tumor development [164].

Pancreatic cancer

The use of CAR T-cells in the therapy of pancreatic malignancies is still being studied. Although current pancreatic cancer CAR T-cell clinical trials have failed to enhance survival, it has the potential to provide valuable opportunities [165, 166]. A number of clinical trials are now underway, intending to define the usage of this therapeutic technique in the near future. Mesothelin, CD133, PSCA, claudin 18.2, EGFR, CEA, MUC1, and HER2 were among the antigens targeted for therapy in these studies [165, 167, 168]. Mesothelin appears to be the most potential CAR target due to its high expression levels, particularly in mesothelioma, pancreatic, and OC [169]. According to the findings, CAR T-meso destroyed pancreatic cancer cells in vitro and suppressed subcutaneous tumor growth in vivo. In addition, CAR T-meso successfully suppressed lung metastases caused by pancreatic cancer [170, 171]. HER2 has been shown to have a 20–60% higher expression level in pancreatic cancer. CAR against HER2 was designed in a study to inhibit the metastasis and growth of pancreatic xenograft cancer in mice [172]. Another strategy involved targeting pancreatic cancer with CAR T-cells against PSCA and protecting CAR T-cells from the immunosuppressive cytokine IL-4 via the inverted cytokine receptor (4/7 ICR) [173]. Zhang E et al. created a dual CAR-modified T-cell to eliminate AsPC-1 pancreatic cells with high CEA and mesothelin expression [174]. Despite developing multiple pancreatic cancer-targeted CARs, pancreatic cancer heterogeneity and the complex and heterogeneous TME pose significant challenges to successful immunotherapy. To circumvent this obstacle, several researchers have coupled CAR T-cells with additional therapies such as checkpoint inhibitors and oncolytic viruses [175]. Furthermore, a study presented a case of Robo1-CAR-NK cell therapy for Pancreatic ductal adenocarcinoma with liver metastasis [176].

Glioblastoma

The utilization of CAR T-cells in glioblastoma (GB) has been limited, owing to the lack of well-described tumor-specific antigens that are expressed homogenously and frequently [177]. Cell surface antigens confined to tumor cells are ideal candidates, as they avoid the toxic effects caused by CAR T-cells recognizing normal organ tissue [178]. Multiple GB antigens have been targeted by CAR T-cells in clinical studies, including interleukin-13
receptor alpha 2 (IL-13Rα2), epidermal growth factor receptor variant III (EGFRvIII), and Her 2 [178, 179]. EGFRvIII is a constitutively activated tyrosine kinase expressed on the surface of GB and is related to GB development and progression. However, EGFRvIII is not found in normal tissue [180]. Anti-EGFRvIII CARs exhibited promise in preclinical treatment models of GB. Animal survival in a mouse glioma model was directly related to the amount of anti-EGFRvIII CARs injected intracerebrally [181]. EGFR-CAR T-cell therapies are currently being studied in multiple phase 1 and phase 2 trials (NCT01454596, NCT03283631, NCT05024175). Another potential target for CAR T-cell therapies is IL-13Rα2-IL-13Rα2, and its overexpression is associated with a poor prognosis in patients with GB [182]. An IL-13Rα2-specific CAR termed IL-13-zetakine and early results from a second-generation 4-1BB costimulatory IL-13-zetakine CAR showed promising clinical activity [183]. Another target is HER2, which has been extensively studied in breast cancer [184]. Increased HER2 expression in GB is linked to a poor prognosis [185]. HER2 is being studied as a potential target in a number of clinical trials (NCT03389230, NCT03423992). Moreover, to target GB-related surface proteins, some therapeutic trials have used genetically modified cytomegalovirus (CMV)-specific T-cells that express CARs [177]. In this context, Ahmed et al. showed that the administration of autologous HER2-CAR-modified virus-specific T-cells (VSTs) could be correlated with clinical benefit in patients with advanced GB [186]. Mucin 1 (NCT02617134), CD147 (NCT04045847), CD133 (NCT03423992), EphA2 (NCT02575261), and GD2 (NCT02575261) are among the other targets for CAR T-cell therapy in gliomas (NCT02617134).

GB treatment using EGFR-CD28-CD3 CAR-NK cells revealed substantial cytotoxic effects and enhanced murine survival in a tumor-bearing mouse model [187]. Other research has found that further genetic modification of these EGFR-CAR-NK cells with the chemokine receptor CXCR4 improved survival in xenograft mice compared to treatment with EGFR-CAR-NK cells [188]. Other trials have targeted CD73 [152], EGFRvIII [189], and HER2 [190] in GB cell lines, with considerable anti-GB activity and tumor lysis. Multi-targeted CAR-NK cells may be an effective method for treating GB due to the immunosuppressive milieu and the tumor heterogeneity [129].

Neuroblastoma

Neuroblastoma is a type of brain cancer with a dismal prognosis that primarily affects children. CAR immunotherapy in neuroblastoma has been shown to be safe and feasible in early phase trials, but there are still significant barriers to its efficacy. These include an immunosuppressive TME, difficulties in identifying targets, and limitation of T-cell persistence and efficacy [191]. Despite the preclinical development of CAR T-cells targeting, a variety of neuroblastoma-associated antigens, only those targeting GD2 and L1-CAM (CD171) have progressed to clinical trials [192, 193]. Besides mixed findings from early GD2 CAR clinical trials, this target continues to be a hot topic. Many preclinical studies targeting GD2 are currently underway, as well as several clinical trials on neuroblastoma patients (NCT02765243, NCT02919046, NCT03373097, NCT03294954, and NCT02761915).

CAR-NK cells have also been studied in Neuroblastoma. In a preclinical experiment, ganglioside GD2-specific CAR-NK cells were employed to treat a multi-drug resistant neuroblastoma cell line and a neuroblastoma xenograft model, which demonstrated significant antitumor activity [194]. Moreover, CD276-NK-92 CAR-NK cells could successfully lyse neuroblastoma monolayer and 3D spheroids [195]. Another study suggests that combining redirected NK cells with either PD-1 or PD-L1 blockers or histone deacetylase inhibitors (HDACi) may be more effective against cancer [196].

Other tumors

There are eleven clinical trials involving CAR cell therapy in melanoma patients. A recent study in humanized mouse models highlights the potential of HER2 as a melanoma target antigen and supports the use of CAR T-cells in patients with highly refractory melanoma [197]. In addition, the use of VEGF-R2-specific CAR T-cells to stop tumor growth by destroying tumor-associated vasculature gave melanoma-bearing mice dramatic survival advantages [198]. Ganglioside GD2 is a well-known antigen in different tumors, including melanoma, and reprogrammed CAR T-cells against GD2 have been shown to lyse primary melanoma cells in vitro and eliminate melanoma in animal models [199]. Furthermore, several clinical trials are investigating the safety and efficacy of CAR T-cells directed against c-MET (NCT03060356), CD20 (NCT03893019), IL13RA2 (NCT04119024), and CD70 (NCT02830724). These clinical trials are phase I or II or single-arm trials which will warrant further investigation if successful.

Hepatocellular carcinoma (HCC) is a lethal type of liver cancer [200]. Some preclinical and clinical evidence suggests that CAR T-cell therapies targeting CEA, MUC-1, and GPC-3 antigens have potent antitumor activity in HCC [201, 202]. The majority of experimental results have come from targeting GPC-3, either with an inducible armored IL-12 construct or by directly eliminating GPC-3 positive HCC cells [203, 204, 205]. Overall, CAR T-cell therapy in HCC still has a long way to go from
bench to bedside. CAR-NK cells have been studied in HCC as well. Yu et al. investigated that anti-glypican-3 (GPC3)-CAR-NK cells against HCC cells induced significantly in vitro cytotoxicity and cytokine release, as well as antitumor in vivo effects in HCC xenograft models [206]. In another investigation, NKG2D-DAP10-CD3ζ-CAR-NK cells exhibited a robust antitumor immune response against HCC cell lines of HCC as well as osteosarcoma, pancreatic cancer, and breast cancer [207]. In addition, Wang et al. modified NK-92 cells for expressing the TN chimeric receptor, which combines the transmembrane domains of NKG2D and extracellular of TGF-type II receptor. They discovered that TN-expressing NK-92 cells were significantly resistant to TGF-β-induced inhibitory signaling and produced significantly more killing capacity and IFN-γ production in vitro against HCC cells [208].

There is limited research on CAR T-cell treatment in gastric cancer [209]. According to a study, developing a CAR T-cell that targets the monoclonal antibody 3H11 produced a favorable response in gastric cancer [210]. Another study revealed that Folate receptor 1 (FOLR1) CAR T-cells could detect and kill FOLR1-positive gastric cancer cells [211]. In the third investigation, the NKG2D ligand was chosen as a target, and the NKG2D-CAR T-cell was found to have cytolytic action against gastric cancer.

Fig. 3 Limitations of chimeric antigen receptor (CAR) T cells. There are several limitations in using CAR-immune cells in tumor therapy, including antigen heterogeneity, limit proliferation and short retention in tumor site, low trafficking and infiltration of CAR T cells to the tumor site, on target off tumor condition, cytokine release syndrome (CRS), and immune-suppressive TME. Abbreviations: PD-1 (programmed cell death protein 1), TAM (tumor associated macrophage), MDSC (Myeloid-derived suppressor cell), T-reg (T regulatory), TAA (tumor associated antigen).
The transient adjustment of target antigens, programmable CAR expression, exploitation of various CAR immune cells, expression of each chimeric receptor in relation to a particular antigen, and expression of a chimeric receptor including two or more antigen recognition domains, which leads to multiple antigens identifying through the single receptor [227]. On the other hand, targeting cancer stem cells closely related to tumor heterogeneity is one of the methods to eliminate tumor heterogeneity. For example, CD133 is a marker of stem cells that is overexpressed in many solid tumors and is now considered a target tumor marker for CAR T-cells [228].

**Tumor antigen escape**

Immune escape is another potential issue [229, 230]. Although CAR T-cells that target a single antigen can achieve high response rates at first, the malignant cells of a significant number of patients administered with these CAR T-cells lose target antigen expression and produce new tumor antigens that the original CAR T-cells may not recognize [7]. Potential solution is targeting the antigens that are expressed on the tumor stroma. The tumor stromal compartment promotes tumor growth by secreting cytokines and growth factors, supplying nutrients, and contributing to tumor-induced immunosuppression [122]. Furthermore, studies which target FAP expressed on cancer-associated fibroblasts or VEGFR-2 expressed on tumor vasculature endothelial cells have shown that tumor stroma is genetically more stable [231, 232]. Furthermore, CAR-expressing NK cells can eradicate malignant cells that lose CAR targeted specific antigen through their innate immune receptors.

**CAR associated toxicities**

Unfortunately, as the potency of CARs was increased, high rates of toxicity were observed. The release of a number of inflammatory cytokines by infused T-cells in response to antigen recognition causes cytokine release syndrome (CRS), a systemic inflammatory response with a large increase in the expression levels of TNF-α, C-reactive protein, IL-2, IL-8, IFN-γ, and most importantly, IL-6. Fever, hypotension, anorexia, fatigue, multi-organ dysfunction, and even sudden death can occur due to the cytokine storm [233, 234]. Another common adverse effect of CAR T-cell therapy is nervous system toxicity, including seizures and confusion [235, 236]. Patients with ALL or lymphoma who received the first FDA-approved CAR T-cell therapy, CD19-directed CARs, have had the most extensive characterization of the toxicities underlying CAR T-cell therapy to date [7]. Researchers are modifying T-cell dose escalation and have introduced the prompt use of inhibitors that block the effects of IL-6 (tocilizumab or siltuximab) or...
TNF-α (Infliximab) to reduce the severity of CRS effects [237, 238]. The identification of CRS biomarkers is another critical issue. Teachey et al. demonstrated that a combination of three cytokines (IFN-γ, soluble IL-1 receptor agonist, and glycoprotein subunit 130) accurately predicted CRS one month after anti-CD19 CAR T-cell infusion for ALL [239]. On the other hand, early promising CAR-NK studies indicate significant lack of CRS or neurotoxicity. So that in the study by Liu et al., administration of anti-CD19 CAR-NK cells was not associated with the development of CRS, neurotoxicity, or GVHD, and there was no increase in inflammatory cytokines, including interleukin-6, above baseline [240].

On-target off-tumor effects
The activation of CAR T-cells by targeting antigen within healthy tissues is causing “on-target, off-tumor” toxicity, which is currently a major concern. This occurs because many TAAs are not tumor-specific and are also expressed at varying levels in normal tissues [241, 242]. On-target toxicity prevention requires the proper selection of antigens with more restricted expression [243]. Other strategies are infusing CAR T-cells with only temporary CAR expression (the expression level decreases with cell division, and transcription gradually becomes diluted) and targeting tumor-specific post-translational modifications such as overexpressed truncated O-glycans in solid tumors [243, 244, 245]. However, the risk of on-target/off-tumor toxicity to normal tissues by CAR-NK cells is low because of the short lifespan of CAR-NK cells in circulation. Moreover, previous research discovered that optimizing the affinity of tumor antigen binding resulted in a CAR with improved selectivity to high tumor antigen density cells and a decreased risk of on-target off-tumor effects [246, 247]. This enhanced therapeutic index was primarily achieved by tuning down the affinity of the scFv antibody for its cognate target antigen sequence. This process seemed to have a greater impact when membrane antigen expression was low. Affinity tuning with purified antigen sequences ignores the spatial arrangement of antigen on the cell membrane. As a risk-mitigation strategy, the approach could increase off-target risk [248].

Limited expansion and persistence
A massive amount of CAR immune cells is required for achieving optimal clinical-scale responses. As the number of immune cells from a single donor is insufficient for treatment, immune cell expansion and activation are critical [249]. The limitations of the strong in vivo persistence and expansion of CAR T-cells, particularly CAR-NK cells, are a major barrier to therapeutic efficacy, while this feature may be desirable in terms of safety [250, 251]. Therefore, CARs can be genetically modified to produce cytokines or add cytokine/cytokine receptors to improve in vivo expansion and persistence while avoiding systemic toxicity [122]. Furthermore, CAR T-cell function may be improved by combining immunotherapy with checkpoint blockade [252]. In addition, exogenous cytokines may be used to expand and activate NK cells [39]. Another way to boost NK cell persistence is to give them a memory-like phenotype by pre-activating them with a cytokine cocktail (IL-12, IL-15, and IL-18) for a brief period to induce differentiation into cytokine-induced memory-like NK cells [253]. Moreover, knocking out the cytokine-inducible sh2-containing protein (CISH) gene, a negative regulator of IL-15 signaling, has been shown to improve NK cell metabolism, persistence, cytotoxicity, and CAR-NK functionality [254]. Notably, in an AML xenograft model, CISH knockout NK cells mediated improved disease control [255]. Besides, researchers optimized the structure of CAR and introduced the IL-15 transgene (iC9/CAR.19/IL15) to increase the persistence time of CAR-NK cells in vivo and reduce treatment-related side effects. In xenogeneic mouse models of lymphoma, such a novel design demonstrated remarkable survival [256].

Immunosuppressive microenvironment
Studies demonstrated that rapid loss of CAR immune cell function limits its therapeutic role in immunosuppressive TME [4]. Different cell types (Tregs, MDSCs, and TAMs) can infiltrate solid tumors and support tumor growth, angiogenesis, and metastasis. In addition to tumor cells, these cells produce growth factors, chemokines, and local cytokines, such as IL-10, VEGF, TGF-β, and IL-4 which stimulate tumor growth and proliferation. Anti-tumor immunity is also reduced by immune checkpoint molecules like CTLA-4, TIM3, PD-L1, and PD-1 [257, 258], and their combinational blockade has shown great promises for cancer treatment [259]. Furthermore, solid tumors frequently show metabolic aberrations that can affect immune cell biology, such as increased metabolism and subsequent depletion of amino acids (e.g., arginine) that are important for immune cell function, also hypoxia and extracellular matrix acidification due to insufficient vascular supply that is hostile to T-cell survival [260]. As a result, various approaches have been employed to arm CAR immune cells against tumor immunosuppressive microenvironment, such as enhancing CAR immune cells performance by altering metabolic profiles to increase cell activity in hostile environments or combining CARs with immune checkpoint inhibitors like monoclonal antibodies. Remarkably, in some types of cancer, including multiple myeloma, mesenchymal stromal cells in the tumor milieu have been found to be involved in
cancer resistance to CAR T-cell therapies by upregulating survivin [101], which has been shown to serve as an anti-apoptotic factor in a variety of pathological conditions [261, 262]. As well, immunomodulatory cytokines like IL-12, which increase the immune response via NK cells and T-cells, can also be used to improve CAR immune cell therapy [263, 264]. Transforming growth factor-beta (TGF-β) CAR T-cells also can help with antitumor immune functions by shielding neighboring immune cells from TGF-β’s immunosuppressive effects [265]. Moreover, dominant-negative receptors like TGF-βRII that act as a sink for immunosuppressive cytokines has been developed and thus improve CAR T-cell function in the TME [266]. Furthermore, silencing an intracellular immune checkpoint in NK cells (CRISPR/Cas9-mediated CISH knockout (CISH KO)) improves their metabolic fitness in the TME and leads to enhanced functions [267].

Limited CAR trafficking and tumor infiltration

Another significant barrier for CAR immune cells in solid tumors is the need for immune cells to extravasate from the bloodstream into solid tissues to facilitate antitumor activity. During these processes, CAR immune cells must attach to endothelial cells and initiate chemokine–chemokine receptor interactions in order to extravasate into tumor areas [260, 268]. On the other hand, CAR T-cell therapy’s efficacy in B-cell malignancies is probably since target B-cells are easily accessible to CAR-T-cells and express a variety of costimulatory receptor ligands that can increase CAR T-cell function [269]. Solid tumor CAR immune cell therapy is limited compared to hematological malignancies due to dysregulation in cytokine secretion by tumor cells and low chemokine receptor expression on CAR immune cells, as well as the existence of a thick fibrotic matrix in solid tumors, which limits CAR’s capacity to migrate and invade cancerous cells [270, 271]. One strategy for overcoming these restrictions is to use localized delivery rather than systemic administration [272]. Another strategy for cancer immunotherapy is to target the chemokine system (which includes chemokines and their receptors) [273].

CAR-modified macrophages

Due to the challenges associated with CAR T-cell and NK cell therapies, CAR macrophages (CAR-M) have recently emerged as an alternative therapeutic intervention. CAR-M cells, same as CAR T- and CAR-NK cells, are composed of extracellular signaling domains that recognize specific TAs, transmembrane regions, and intracellular domains [274]. Currently, research into the extracellular signal domain has identified several common tumor targets, such as HER2 (NCT04660929). CAR-M research focuses on activating and enhancing the phagocytic effect through various intracellular domains [274].

CAR macrophages have unique benefits over CAR T-cells in overcoming some major barriers in solid tumors. While T-cells are unable to enter the tumor microenvironment (TME) due to physical barriers formed by the matrix surrounding the tumor cells, macrophages can immerse significantly in the TME [275]. TAM plays a key role in immune suppression, tumor invasion and metastasis [276]. CAR-M can decrease TAM ratios and change TAM cellular phenotypes, which has positive effects on tumor treatment. Besides tumor cell phagocytosis, CAR-M can promote antigen presentation and enhance the cytotoxic effects of T-cells. Furthermore, CAR-M has a shorter time in circulation and less non-tumor toxicity than CAR T [277]. Moreover, macrophages can sense hypoxia and its metabolites, such as low pH, and migrate into the TME [278].

Although CAR-M has the potential to be potent cancer immunotherapy, however, CAR-M is still in its early stages, with only two clinical trials being initiated (NCT05007379, NCT04660929) launched and no results reported. As a result, many limitations have not yet been uncovered. Significant efforts are underway to optimize CAR macrophage structure, manufacturing, storage, tumor infiltration, and retention to cytotoxicity. Repeated dosing may be required to keep CAR macrophage levels high enough for active cancer surveillance [278].

Conclusion

Based on collective evidence, CAR immune cell-based cancer therapy has become a compelling and advanced research area for targeting malignant cells. Despite significant challenges, several investigations are being conducted to address these constraints. The further success of CAR immune cell therapy will strongly depend on the development of CAR constructs optimally suited for individual applications, the development of toxicity reduction strategies, identification of the most appropriate cell types to express CARs and the possibility to safely and completely remove CAR cells upon achievement of complete remission of the respective disease. Once resolved, CAR cell therapy may become an effective, affordable, and safe treatment for malignancies.

Abbreviations

TRUCKs: T-cells redirected for universal cytokine killing; PSCA: Prostate stem-cell antigen; HSCT: Allo-hematopoietic stem-cell transplantation; GVHD: Graft-versus-host disease; PBMCs: Peripheral blood mononuclear cells; HPCs: Hematopoietic progenitor cells; iPSCs: Induced pluripotent stem cells; GM-CSF: Granulocyte–macrophage colony-stimulating factor, axi-cel: Axicabtagene; AML: Acute myeloid leukemia; CLL: Chronic lymphocytic leukemia;
Keshavarz et al. Stem Cell Research & Therapy (2022) 13:482

BCMA: B-cell maturation antigen; TNF: Tumor necrosis factor; EpCAM: Epithelial cell adhesion molecule; EGFR: Epidermal growth factor receptor; TNBC: Triple-negative breast cancer; VEGF-R2: Vascular endothelial growth factor receptor 2; CRC: Colorectal cancer; TAG: Tumor-associated glycoprotein; GB: Glioblastoma; CRS: Cytokine release syndrome; CAR-MA: CAR macrophages; TME: Tumor microenvironment; TGF-β: Transforming growth factor-beta.

Acknowledgements
Not applicable.

Author contributions
All authors contributed to the conception and the main idea of the work. AK, AS, SK, YS, NN, MSK, and SM drafted the main text, figures, and tables. SJ and FF supervised the work and provided the comments and additional scientific information. AM and RA also reviewed and revised the text. All authors read and approved the final version of the work to be published.

Funding
No Funders.

Availability of data and materials
Not applicable.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
There is no conflict of interests.

Author details
1. Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 2. Department of Oral and Maxillofacial Radiology, School of Dentistry, Islamic Azad University, Isfahan (Khoasgan) Branch, Isfahan, Iran. 3. Department of Orthodontics, School of Dentistry, Alborz University of Medical Sciences, Karaj, Iran. 4. Department of General Surgery, School of Medicine, Arak University of Medical Sciences, Arak, Iran. 5. Department of Endodontics, School of Dentistry, Birjand University of Medical Sciences, Birjand, Iran. 6. Alborz University of Medical Sciences, Karaj, Iran. 7. Department of Paramedical, Kurdistan University of Medical Sciences, Sanandaj, Iran. 8. Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 9. Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. 10. Department of Endodontics, College of Stomatology, Stomatological Hospital, Xi'an Jiaotong University, Shaanxi, People's Republic of China. 11. Department of Prosthodontics, School of Dentistry, Hamadan University of Medical Sciences, Hamadan, Iran.

Received: 21 January 2022  Accepted: 12 August 2022  Published online: 24 September 2022

References

1. Grupp SA, et al. Chimeric antigen receptor–modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509–18.
2. Maude SL, et al. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia Blood. J Am Soc Hematol. 2015;125(26):4017–23.
3. Hartmann J, et al. Clinical development of CART cells—challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med. 2017;9(9):1183–97.
4. Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CART T-cell therapy. Nat Rev Clin Oncol. 2020;17(3):147–67.
5. Feins S, et al. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94(5):S1–S9.
6. Albigner N, Hartmann J, Ullrich E. Current status and perspective of CART and CAR-NK cell therapy trials in Germany. Gene Ther. 2021;28:9(3):S13–27. https://doi.org/10.1038/s41434-021-00246-6.
7. Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):1–11.
8. Galli F, et al. Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy. J Exp Clin Cancer Res. 2020;39:1–21.
9. Dinita Devi N, Chyrmang D, Baidya K, Devi Y. Askin Tumor: A Case Report of a Rare Tumor. Int J Sci Res Dental Med Sci. 2021;3(3):153-155. https://doi.org/10.30485/ijsrmeds.2021.300418.1183.
10. Xia A, et al. T cell dysfunction in cancer immunity and immunotherapy. Front Immunol. 2019;10:1719.
11. Martinez M, Moon EK. CART cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front Immunol. 2019;10:128.
12. Ferrone S, Whiteside TL. Tumor microenvironment and immune escape. Surg Oncol Clin N Am. 2007;16(4):755–74.
13. Van Schandevel S, Kerne T. Chimeric antigen receptor T-cell therapy: design improvements and therapeutic strategies in cancer treatment. Acta Clin Belgica. 2018;75(1):26–32. https://doi.org/10.1080/17843286. 2018.1543533.
14. Mardi A, et al. Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; combination of oncolytic virus-based immunotherapy and CART therapy for ICD induction. Cancer Cell Int. 2022;22(1):168.
15. Calendo F, Dukhnina M, Siciliano V. Engineered cell-based therapeutics: synthetic biology meets immunology. Front Bioeng Biotechnol. 2019;7:43.
16. Si W, Li C, Wei P. Synthetic immunology: T-cell engineering and adoptive immunotherapy. Synthetic Syst Biotech. 2018;3(3):179–85.
17. Hughes-Parry HE, Cross RS, Jenkins MR. The evolving protein engineering in the design of chimeric antigen receptor T cells. Int J Mol Sci. 2020;21(1):204.
18. Tokarew N, et al. Teaching an old dog new tricks: next-generation CART cells. Br J Cancer. 2019;120(1):26–37.
19. Chen L, Files DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227–42.
20. Cheadle EJ, et al. CART cells: driving the road from the laboratory to the clinic. Immunol Rev. 2014;257(1):91–106.
21. Winkove R, et al. Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. Clin Transl Immunol. 2019;8(5):e1049.
22. Zhang C, et al. Engineering car-t cells: Biomarker Res. 2017;5(1):1–6.
23. El-Daly SM, Hussein J. Genetically engineered CART-immune cells for cancer therapy: recent clinical developments, challenges, and future directions. J Appl Biomater. 2019;17(1):11–11.
24. Li J, et al. Chimeric antigen receptor T cell (CART) immunotherapy for solid tumors: lessons learned and strategies for moving forward. J Hematol Oncol. 2018;11(1):1–18.
25. Chmielewski M, Abken H. TRUCks: the fourth generation of CARs. Expert Opin Biol Ther. 2015;15(8):1145–54.
26. Yilmaz A, et al. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy. J Hematol Oncol. 2020;13(1):1–22.
27. Daheer M, Rezvani K. Outlook for new CAR-based therapies with a focus on CAR NK cells: what lies beyond CAR-engineered T cells in the race against cancer. Cancer Discov. 2021;11(1):45–58.
28. Wen S, et al. CART bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: a case report. BMC Cancer. 2018;18(1):1–7.
29. Liu J, et al. Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies. J Hematol Oncol. 2017;10(1):1–8.
30. Morgan MA, et al. Use of cell and genome modification technologies to generate improved "off-the-shelf" CART T and CAR NK cells. Front Immunol. 2020;11:1965.
31. Schönfeld K, et al. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther. 2015;23(2):330–8.
32. Wrona E, Borowiec M, Potemski P. CAR-NK Cells in the Treatment of Solid Tumors. Int J Mol Sci. 2021;22(11):5899.
33. Yang Y, et al. Superior expansion and cytotoxicity of human primary NK and CAR-NK cells from various sources via enriched metabolic pathways. Mol Ther Methods Clin Dev. 2020;18:249–45.
34. Herrera L, et al. Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells. Sci Rep. 2019;9(1):1–10.
35. Luevano M, et al. The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation. Hum Immunol. 2012;73(3):248–57.
36. Sowa Y, et al. Direct conversion of human fibroblasts into Schwann cells that facilitate regeneration of injured peripheral nerve in vivo. Stem Cells Transl Med. 2017;6(4):1207–16.
37. Hermanson DL, et al. Induced pluripotent stem cell-derived natural killer cells for treatment of ovarian cancer. Stem Cells. 2016;34(1):93–101.
38. Sarker A, Sorkhob AD, Ahmad H, Abdulmohammadi-Vahid S, Parhizkar F, Yousefi M, Aghabati-Maleki L. Allogeneic lymphocytes immunotherapy in female infertility: lessons learned and the road ahead. Life Sci. 2022;229:120503. https://doi.org/10.1016/j.lfs.2022.120503.
39. Xie G, et al. CAR-NK cells: a promising cellular immunotherapy for cancer. EBioMedicine. 2020;59:102975.
40. Lieberman J. Anatomy of a murder: how cytotoxic T cells and NK cells are activated, develop, and eliminate their targets. Immune Rev. 2010;235(1):S5–9.
41. Basar R, Daher M, Rezvani K (2020) Next-generation cell therapies: The emerging role of CAR-NK cells. Hematology 2014, the American Society of Hematology Education Program Book. 2020(1): 570-8.
42. Wang L, et al. Chimeric antigen receptor (CAR)-modified NK cells against cancer: opportunities and challenges. Int Immunopharmacol. 2019;74:105695.
43. Siegler EL, et al. Off-the-shelf CAR-NK cells for cancer immunotherapy. Cell Stem Cell. 2018;23(2):160–1.
44. Hui L, et al. From CAR-T cells to CAR-NK cells: a developing immuno-therapy method for hematological malignancies. Front Oncol. 2021. https://doi.org/10.3389/fonc.2021.720501.
45. Herrera L, et al. The Race of CAR therapies: CAR-nk cells for fighting b-cell hematological cancers. Cancers. 2021;13(21):5418.
46. Ingegnere T, et al. Human CAR NK cells: a new non-viral method allowing high efficient transfection and strong tumor cell killing. Front Immunol. 2019;10:957.
47. Bald T, et al. The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies. Nat Immunol. 2020;21(8):835–47.
48. Hu Y, Tian Z-G, Zhang C. Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy. Acta Pharmacol Sin. 2018;39(2):167–76.
49. Geller MA, Miller JS. Use of allogeneic NK cells for cancer immunothera-apy: Immunotherapy. 2011;3(2):1445–59.
50. Morandi F, et al. Engineering the bridge between innate and adaptive immunity for cancer immunotherapy: focus on γδ T and NK cells. Front Immunol. 2019;10:957.
51. Feng F, et al. Relaxed cytotoxicity is associated with high expression of the γδ T cell receptor CD8α in human tissues. J Immunol. 2017;198(5):1968–76.
52. Chen K, et al. Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor. Leukemia. 2017;31(10):2151–60.
53. Rafiq S, Brentjens RJ. Tumors evading CARs—the chase is on. Nat Med. 2018;24(10):1492–3.
54. Harrer DC, Dörrie J, Schaft N. Cspg4 as target for CAR-T-cell therapy for multiple myeloma-associated κ light chains. J Clin Investig. 2016;126(7):2589–96.
55. Zhao Z, et al. The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. Acta Pharmacuetica Sinica B. 2018;4(4):539–51.
56. Abramson JS, Lunning M, Palomba ML. Chimeric antigen receptor T-cell therapies for aggressive B-cell lymphomas: current and future state of the art. Am Soc Clin Oncol Educ Book. 2019;39:446–53.
57. Neelapu SS, et al. Axicabtagene ciloleucel CAR-T cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–44.
58. Alam A, Jagat R, Maniram RS, Bhimte A. Assessment of haematological profile and CD4 count of patients with HIV infection. Int J Sci Res Dental Med Sci. 2022;4(2):45–51. https://doi.org/10.30164/ijsrds.2022.332436.1266.
59. Schuster SJ, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56.
60. Wang M, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331–42.
61. Killock D, KTE-X19 efficacious in adults with B-ALL. Nat Rev Clin Oncol. 2021;18(8):470–470. https://doi.org/10.1038/d41571-021-00357-6.
62. Abramson JS, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–52.
63. Wang Y, et al. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. Clin Immunol. 2014;155(2):160–75.
64. Onoe A, Jazirehi AR. CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of refractory or refractory B-cell Non-Hodgkin’s Lymphomas. Am J Cancer Res. 2016;6(2):403.
65. Ramos CA, et al. Anti-CD30 CAR-T Cell Therapy in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2020;38(32):5794.
66. Raifei H, Daher M, Rezvani K. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity. Br J Haematol. 2021;193(2):216–30.
67. Liu E, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018;32(2):520–31.
68. Chu Y, et al. Targeting CD20+ aggressive B-cell non-Hodgkin lymphoma by anti-CD20 CAR mRNA-modified expanded natural killer cells in vitro and in NSG mice. Cancer Immunol Res. 2015;3(4):333–44.
69. Chen K, et al. Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor. Leukemia. 2018;32(1):1–8.
70. Rafei H, Daher M, Rezvani K. Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity. Br J Haematol. 2021;193(2):216–30.
71. Ulasi T, Nri-Ezedi C, Ofiaeli O, Chijioke E. Novel cases of diamond blackfan anaemia in two nigerian toddlers: roadmap for care in resource-limited nations. Int J Sci Res Dental Med Sci. 2021;3(2):101–5.
72. Lusalis T, Niri-Ezedi C, Ofiaeli O, Chijioke E. Novel cases of diamond blackfan anaemia in two nigerian toddlers: roadmap for care in resource-limited nations. Int J Sci Res Dental Med Sci. 2021;3(2):101–5. https://doi.org/10.30485/ijsrmds.2022.286671.02.
73. Lemal R, Tournihac O. State-of-the-art for CAR-T cell therapy for chonic lymphocytic leukemia in 2019. J Immunother Cancer. 2019;7(1):1–6.
74. Watanabe K, et al. Target antigen density governs the efficacy of anti-CD20-CD28-CD3ζ chimeric antigen receptor–modified effector CD8+ T cells. J Immunol. 2015;194(3):911–20.
75. Hudecek M, et al. The B-cell tumor–associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood. J Am Soc Hematol. 2010;116(22):4532–41.
76. Giordano Attianese GMP, et al. In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor. Blood J Am Soc Hematol. 2011;117(18):4736–45.
77. Rames CA, et al. Clinical responses with T lymphocytes targeting malignancy-associated k light chains. J Clin Investig. 2016;126(7):2588–96.
82. Porter DL, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015; https://doi.org/10.1126/scitranslmed.aac5150.

83. van Bruggen JA, et al. Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy. Blood J Am Soc Hematol. 2019;134(1):44–58.

84. Mardiana S, Gill S. CAR T cells for acute myeloid leukemia: state of the art and future directions. Front Oncol. 2020;10:697.

85. Mardiros A, Forman SJ, Budde LE. T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia. Curr Opin Hematol. 2015;22(6):484.

86. Ritchie DS, et al. Persistence and efficacy of second generation CAR T cell against the LeY′ antigen in acute myeloid leukemia. Mol Ther. 2013;21(11):2122–9.

87. Lynn RC, et al. Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells. Blood J Am Soc Hematol. 2015;125(22):3468–76.

88. Kim MY, et al. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell. 2018;173(6):1439–1453.e19. https://doi.org/10.1016/j.cell.2018.05.013.

89. Cummins KD, Gill S. Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality? Haematologica. 2019;104(7):1101–8.

90. Haubner S, et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML Leukemia. 2019;33(1):64–74.

91. Holstein SA, Lunning MA. CART-T cell therapy in hematologic malignancies: a voyage in progress. Clin Pharmacol Ther. 2020;107(1):112–22.

92. Jetani H, et al. CART-T-cells targeting FLT3 have potent activity against FLT3–ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib. Leukemia. 2018;32(5):1168–79.

93. Tang X, et al. First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Int J Cancer. 2019;145(7):1935–45.

94. Oelsner S, et al. Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth. Int J Cancer. 2019;145(7):1935–45.

95. Oelsner S, et al. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma. Cytotherapy. 2017;19(2):235–49.

96. Klöö S, et al. Optimization of human NK cell manufacturing: fully automated separation, improved ex vivo expansion using IL-21 with autologous feeder cells, and generation of anti-CD123-CAR-expressing effector cells. Hum Gene Ther. 2017;28(10):897–913.

97. Salman H, et al. Preclinical targeting of human acute myeloid leukemia using CD44-specific chimeric antigen receptor (CAR) T cells and NK cells. J Cancer. 2019;10(18):4408.

98. Kumar S. Natural killer cell cytotoxicity and its regulation by inhibitory receptors. Immunology. 2018;154(3):383–93.

99. Jamali S, Ahmadi F, Mahdavi-Mazdeh M, Tavoosi A. The Relationship between serum uric acid level and pulmonary artery hypertension in patients with chronic renal failure. Int J Sci Res Dental Med Sci. 2019;10(24):2369–75.

100. Xie Y, et al. CAR T-cell therapy for triple-negative breast cancer: Where we are. Cancer Lett. 2020;491:121–31.

101. Elahi R, Heidary AH, Hadiloo K, Esmaeilzadeh A. Chimeric antigen receptors in triple-negative breast cancer. Breast Cancer Res Treat. 2012;132(2):799–804.

102. Elahi R, Heidary AH, Hadiloo K, Esmaeilzadeh A. Chimeric antigen receptor-engineered natural killer (car nK) cells in cancer treatment; recent advances and future prospects. Stem Cell Rev. 2021;17(6):2081–106. https://doi.org/10.1007/s12015-021-10246-3.

103. Hu Z. Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer. Sci Rep. 2020;10(1):11–13.

104. Elahi R, Heidary AH, Hadiloo K, Esmaeilzadeh A. Chimeric antigen receptor-engineered natural killer (car nK) cells in cancer treatment; recent advances and future prospects. Stem Cell Rev. 2021;17(6):2081–106. https://doi.org/10.1007/s12015-021-10246-3.

105. Hu Z. Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer. Sci Rep. 2020;10(1):11–13.

106. Liu Y, et al. Targeting epithelial growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor. Cell Prolif. 2020;53(6):e12685.

107. Schmitt A, et al. Engineering an optimized trimERIC APRIL-based CAR to broaden targetability of multiple myeloma. Blood. 2018;132(Supplement 1):2059–2059.

108. Sun C, et al. Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma. Oncotarget. 2019;10(24):2369.

109. Gogishvili T, et al. SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes. Blood J Am Soc Hematol. 2017;130(26):2838–47.

110. Smith EL, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CART cells. Sci Transl Med. 2019. https://doi.org/10.1126/scitranslmed.aau7746.
133. Chatterjee M, et al. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Curr Res. 2006;6(2):1181–90.

134. Yu S, et al. Chimeric antigen receptor T cells: a novel therapy for solid tumors. J Hematol Oncol. 2017;10(1):1–13.

135. Soundara Rajan T, et al. In vitro-transcribed mRNA chimeric antigen receptor T cell (IVT mRNA CART) therapy in hematologic and Solid tumor management: a preclinical update. Int J Mol Sci. 2020;21(18):6514.

136. Singh AP, et al. Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer. Lancet Oncol. 2008;9(11):1076–85.

137. Chekmasova AA, et al. Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clin Cancer Res. 2010;16(14):3594–606.

138. Hung C-F, et al. Development of anti-human mesothelin-targeted chimeric antigen receptor messenger RNA–transfected peripheral blood lymphocytes for ovarian cancer therapy. Hum Gene Ther. 2018;29(5):614–25.

139. Schutsky K, et al. Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor. Oncotarget. 2015;6(30):2891–906. https://doi.org/10.1038/ijic.2015.251.

140. Mackay HJ, et al. Phase I/II study of intraperitoneal chemotherapy after neoadjuvant immunochemotherapy for pancreatic cancer. Cancers. 2020;12(6):1389.

141. Sankapithlu VB, Maryanna GD, Shankar K, Kumar Hassan Raghunath S, SheehanHali Thimmaiah K. Blood indices replace upper gastrointestinal endoscopy for the prediction of clinically significant esophageal varices in liver cirrhosis. Int J Clin Res Dental Med Sci. 2021;3(3):105–10. https://doi.org/10.30485/jordms.2021.288512.1163.

142. Cao B, et al. Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer. Biochem Biophys Res Commun. 2020;524(1):96–102.

143. Ng YY, Tay JC, Wang S. CXCR1 expression to improve anti-cancer therapeutic efficacy. Oncotarget. 2016;7(27):44904–10. https://doi.org/10.18632/oncotarget.14443.

144. Shahverdi M, et al. The regulatory role of autophagy-related miRNAs in immune checkpoint blockade resist tumor-mediated inhibition. J Clin Investig. 2018;128(11):4769–80. https://doi.org/10.1172/jci.insight.126345.

145. Wu AA, Jaffee E, Lee V. Current status of immunotherapies for treating pancreatic cancer. Curr Oncol Rep. 2019;21(7):1–11.

146. Li H, et al. CAR-T cells for Colorectal Cancer: Target-selection and strategies for improved activity and safety. J Cancer. 2021;12(6):1804.

147. Apicario C, et al. Cell therapy for colorectal cancer: the promise of chimeric antigen receptor (CAR) T cells. Int J Mol Sci. 2021;22(21):11781.

148. Ozawa H, et al. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J Hematol Oncol. 2017;10(1):1–14.

149. Zhang C, et al. Phase I escalating-dose trial of CAR-T therapy targeting CEA+ metastatic colorectal cancers. Mol Ther. 2017;25(5):1248–58.

150. Kat S, et al. Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery. Cancer Gene Ther. 2016;23(5):142–8.

151. Ang WX, et al. Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis. Oncotarget. 2017;8(8):13545.

152. Dong X, et al. Antitumor activity of NKGD2 CAR-T cells against human colorectal cancer cells in vitro and in vivo. Ann J Cancer Res. 2019;9(5):945.

153. You F, et al. Phase I clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells. Sci China Life Sci. 2016;59(4):386–97.

154. Magee MS, et al. Human GLYC2C-targeted chimeric antigen receptor (CAR)-expressing T cells eliminate colorectal cancer metastases. Cancer Immunol Immunother. 2018;67(6):509–16.

155. Zhang Q, et al. Combination therapy with EpCAM-CAR-NK-92 cells and regorafenib against human colorectal cancer models. J Immunol Res. 2018;2018:1–11. https://doi.org/10.1155/2018/4263520.

156. Henze J, et al. Enhancing the efficacy of CAR-T cells in the tumor micro-environment of pancreatic cancer. Cancers. 2020;12(6):1389.

157. Sur D, et al. Chimeric antigen receptor T-cell therapy for colorectal cancer in advanced microphysiologic 3D tumor models. JCI Insight. 2019;4(21):1–14. https://doi.org/10.1172/jci.insight.126345.

158. Sankapithlu VB, Maryanna GD, Shankar K, Kumar Hassan Raghunath S, SheehanHali Thimmaiah K. Blood indices replace upper gastrointestinal endoscopy for the prediction of clinically significant esophageal varices in liver cirrhosis. Int J Clin Res Dental Med Sci. 2021;3(3):105–10. https://doi.org/10.30485/jordms.2021.288512.1163.

159. Lalali NM, et al. Overexpression of HER-2/neu oncogene and transi- tional cell carcinoma of the bladder. Urol J. 2007;4(3):151–4.

160. Mohammed S, et al. Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvi- ronment of pancreatic cancer. Mol Ther. 2017;25(1):249–58.

161. Zhang E, et al. Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy. J Hematol Oncol. 2018;11(1):1–14.

162. Wu AA, Jaffe E, Lee V. Current status of immunotherapies for treating pancreatic cancer. Curr Oncol Rep. 2019;21(7):1–11.

163. Li C, et al. Robo1-specific chimeric antigen receptor natural killer cell therapy for pancreatic ductal adenocarcinoma with liver metastasis. J Cancer Res Ther. 2020;16(2):393.

164. Daai Sorkhabi A, et al. The basis and advances in clinical applica- tion of cytomegalovirus-specific cytotoxic T cell immunotherapy for glioblastoma multiforme. Front Oncol. 2022;12:818447.

165. Mooney J, et al. Current approaches and challenges in the molecular therapeutic targeting of glioblastoma. World Neururosurg. 2019;129:90–100.

166. Sahin A, et al. Development of third generation anti-EGFRvIII chimeric T cells and EGFvIII-expressing artificial antigen presenting cells for adop- tive cell therapy for glioma. PLoS ONE. 2018;13(7):e0199414.

167. Sampson JH, et al. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Sem Immunol. 2008;20(5):267–75. https://doi.org/10.1016/j.smim.2008.04.001.

168. Choi BD, et al. Intracerebral delivery of a third generation EGFRvIII+ chimeric antigen receptor is efficacious against human glioma. J Clin Neurosci. 2014;21(1):189–90.
182. Thaci B, et al. Significance of interleukin-13 receptor alpha 2–targeted glioblastoma therapy. Neuro Oncol. 2014;16(10):1304–12.

183. Brown CE, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med. 2016;375(26):2561–9.

184. Esteva FI, et al. Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol. 2019;20(5):e175–86.

185. Clark PA, et al. Activation of multiple ERBB family receptors mediates glioblastoma stem-like cell resistance to EGFR-targeted inhibition. Neoplasia. 2012;14(5):420-413.

186. Ahmed N, et al. Her2-specific chimeric antigen receptor–modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA Oncol. 2017;3(8):1094–101.

187. Han J, et al. CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells. Sci Rep. 2015;5(1):1–13.

188. Müller N, et al. Engineering NK cells modified with an EGFRvIII-specific CAR to overexpress CXCR4 improves immunotherapy of CXCL12/SDF-1α-secreting glioblastoma. J Immunother. 2015;38(5):599–56.

189. Zhang C, et al. Folate receptor 1 (FOLR1) targeted chimeric antigen receptor to overexpress CXCR4 improves immunotherapy of CXCL12/SDF-1α-secreting glioblastoma. J Immunother. 2015;38(5):197–210. https://doi.org/10.1097/JCI.0000000000000828.

190. Han H, et al. Monoclonal antibody 3H11 chimeric antigen receptors targeting VEGFR-2 inhibits the growth of vascularized syngenic colorectal xenografts. J Immunother. 2015;38(5):197–210. https://doi.org/10.1097/JCI.0000000000000828.

191. Kim M, et al. Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer. PLoS ONE. 2018;13(6):e0198347.

192. Tao K, et al. Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment. Cancer Chemother Pharmacol. 2018;82(5):815–27.

193. Jiang H, et al. Claudin18. 2-specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer. J Natl Cancer Inst. 2019;111(4):409–18.

194. Yu YD, Kim TJ. Chimeric antigen receptor-engineered T cell therapy for the management of patients with metastatic prostate cancer: a comprehensive review. Int J Mol Sci. 2021;22(2):640.

195. Scheepsi G, et al. CAR-T cell therapy: a potential new strategy against prostate cancer. J Immunother. 2019;42(1):1–11.

196. Kiessling A, et al. Tumor-associated antigens for specific immunotherapy of prostate cancers. Cancers. 2012(4):193–217.

197. Töpfer K, et al. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy. J Immunol. 2015;194(7):3201–12.

198. Montaguer IM, et al. Anti-PiSMA CAR-engineered NK-92 cells: an off-the-shelf cell therapy for prostate cancer. Cells. 2020;9(6):1382.

199. Scheepsi G, et al. Potential application of chimeric antigen Receptor (CAR)-T Cell therapy in renal cell tumors. Front Oncol. 2020;10:1909.

200. Solano N, Perez L, Rivera E, Medina C. Hybrid odontogenic tumor with a unique presentation of the calcifying epithelial odontogenic tumor, adenomatoid odontogenic tumor, and calcifying odontogenic cyst: a case report. Int J Sci Res Dental Med Sci. 2021;3(1):50–4. https://doi.org/10.30485/ijsrmds.2021.269482.1106.

201. Titov A, et al. The biological basis and clinical symptoms of CAR-T therapy-associated toxicities. Cell Death Dis. 2018;9(9):1–15.

202. Schubert M-L, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32(1):34–48.

203. Messmer AS, et al. CAR T-cell therapy and critical care. Wiener klinische Wochenschrift. 2021;133:1318–25.

204. Zhang E, Gu J, Xu H. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors. Mol Cancer. 2018;17(1):1–12.

205. Vyas M, Müller R, Poggio von Strandmann E. Antigen loss variants: catching hold of escaping foes. Frontiers in immunology. 2017;8:175.

206. Zhang C, et al. Chimeric antigen receptor-engineered T-cell therapy for liver cancer. Hepatobiliary Pancreat Dis Int. 2018;17(4):301–9.

207. Shen S, et al. Modulation of anti-tumour activity of ex vivo expanded NK and GD2CAR-NK cells against neuroblastoma. Cytotherapy. 2019;21(9):S20.

208. Wang Z, et al. Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKGD2. Cancer Immunol Immunother. 2017;66(4):537–48.
236. Denton CC, et al. Bilateral retinal detachment after chimeric antigen receptor T-cell therapy. Blood Adv. 2020;4(10):2158.

237. Di Stasi A, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365:1673–83.

238. Arber C, et al. The immunogenicity of virus-derived 2A sequences in lymphoid tumors. N Engl J Med. 2020;382(6):545–53.

239. Gargett T, Brown MP. The inducible caspase-9 suicide gene system for safe CAR T cell therapy. Annu Rev Pharmacol Toxicol. 2016;56:59–83.

240. Liu E, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382(6):545–53.

241. Gargett T, Brown MP. The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol. 2014;5:235.

242. Yu S, et al. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. Mol Cancer. 2019;18(1):1–13.

243. Zhao Y, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate resolution of human disseminated tumors. Can Res. 2010;70(22):9053–61.

244. Gross G, Eshhar Z. Therapeutic potential of T cell chimeric antigen receptors (CARs) in cancer treatment: counteracting off-tumor toxicities for safe CAR T cell therapy. Annu Rev Pharmacol Toxicol. 2016;56:59–83.

245. Steentoft C, et al. Glycan-directed CAR-T cells. Glycobiology. 2019;28(9):656–60.

246. Drent T, et al. A rational strategy for reducing on-target off-tumor effects of CD38-chimeric antigen receptors by affinity optimization. Mol Ther. 2017;25(8):1946–58.

247. Liu X, et al. Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice. Can Res. 2015;75(17):3956–607.

248. Ma P, et al. Avidity-based selection of tissue-specific CAR-T cells from a combinatorial cellular library of CARs. Adv Sci. 2021;8(6):2003091.

249. Lesch S, et al. Determinants of response and resistance to CAR T cell therapy in seminars in cancer biology. Elsevier, 2020.

250. Dana H, et al. CAR-T cells: early successes in blood cancer and challenges in solid tumors. Acta Pharmacaceutica Sinica B. 2021;31(5):1129–47.

251. Chiechibam L, et al. Overhauling CAR T cells to improve efficacy, safety and cost. Cancers. 2020;12(9):2360.

252. Chong EA, et al. PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR. Blood J Am Soc Hematol. 2017;129(8):1039–41.

253. Gang M, et al. Memory-like natural killer cells for cancer immunother- apy in seminars in hematology. Elsevier, 2020.

254. Gurney M, O’Dwyer M. Realizing innate potential: CAR-NK cell therapies for acute myeloid leukemia. Cancers. 2016;8(9):102–9.

255. Zhu H, et al. Deletion of CISH in human pluripotent stem cell-derived natural killer cells enhances anti-tumor activity via metabolic reprogramming. Blood. 2019;134:619.

256. Liu E, et al. Cord blood derived natural killer cells engineered with a chimeric antigen receptor targeting CD19 and expressing IL-15 have long term persistence and exert potent anti-leukemia activity. Blood. 2015;126(23):3091.

257. Binnewies M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–50.

258. Zhao Z, et al. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment. Sci China Life Sci. 2020;63(2):180–205.

259. Sorkhabi AD, et al. Cancer combination therapies by silencing of CTLA-4, PD-L1, and TIM3 in osteosarcoma. IUBMB Life. 2022;74(9):908–17. https://doi.org/10.1002/iub.2655.

260. Beatty GL, O’Hara M. Chimeric antigen receptor-modified T cells for the treatment of solid tumors: defining the challenges and next steps. Pharmacol Ther. 2016;166:30–9.

261. Shomali N, et al. Dysregulation of Survivin-targeting micromolecules in autoimmune diseases: new perspectives for novel therapies. Front Immunol. 2022;13:839945.

262. Shomali N, Baradaran B, Daii Sorkhabi A, Sarkesh A, Kahizi MS, Tosan F, Mahmodpoor A, Mardi A, Mohammadi H, Hassanzadeh A, Saeedi H, Hajiollahi M, Hemmatzadeh M, Marofi F, Sandoghchian Shotorbani S. Survivin, a novel therapeutic target that correlates with survival of autoreactive T lymphocytes obtained from patients with ankylosing spondylitis. Gene. 2022;844(146829). https://doi.org/10.1016/j.gene.2022.146829.

263. Hoskin DW, et al. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells. Int J Oncol. 2008;32(3):527–35.

264. Yeku GO, et al. Armored CART T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci Rep. 2017;7(1):1–14.

265. Chang ZI, Hou AJ, Chen YY. Engineering primary T cells with chimeric antigen receptors for rewired responses to soluble. Leukemia. 2014;27(7):1507–17.

266. Kloss CC, et al. Dominant-negative TGF-β receptor enhances PSMA-targeted human CART T cell proliferation and augments prostate cancer eradication. Mol Ther. 2018;26(7):1855–66.

267. Chen S. Releasing the brake in CAR natural killer cells. Blood J Am Soc Hematol. 2021;137(5):579–81.

268. Di Stasi A, et al. T lymphocytes coexpressing CCRI and a chimeric antigen receptor targeting CD30 have improved homing and anti-tumor activity in a Hodgkin tumor model. Blood J Am Soc Hematol. 2009;113(25):6392–402.

269. Cheadle E, et al. Ligation of the CD20 co-stimulatory receptor enhances IL-2 production from first-generation chimeric antigen receptor T cells. Gene Ther. 2012;19(11):1114–20.

270. Guo J, Tang Q. Recent updates on chimeric antigen receptor T cell therapy for hepatocellular carcinoma. Cancer Gene Ther. 2021;28(10):1075–87.

271. Rahimmanesh I, Khanahmad H. Chimeric antigen receptor-T cells immunotherapy for targeting breast cancer. Res Pharmaceut Sci. 2021;16(5):447.

272. Murad JP, et al. Effective targeting of TAG72+ peritoneal ovarian tumors via regional delivery of CAR-engineered T cells. Front Immunol. 2018;9:2268.

273. Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer micro-environment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559–72.

274. Chen Y, et al. CAR-macrophage: a new immunotherapy candidate against solid tumors. Biomed Pharmacother. 2021;139:111605.

275. Yoon DH, et al. Incorporation of immune checkpoint blockade into chimeric antigen receptor T cells (CAR-Ts): combination or built-in CAR-T. Int J Mol Sci. 2018;19(2):344–55.

276. Pan K, et al. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 2022;41(1):1–21.